NCT02601014View on ClinicalTrials.gov

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 15, 2016

Primary Completion Date

December 3, 2020

Study Completion Date

October 6, 2021

Conditions
Prostate CancerRecurrent Prostate CarcinomaStage IV Prostate Adenocarcinoma
Interventions
BIOLOGICAL

Ipilimumab

Given 1 mg/kg IV

BIOLOGICAL

Nivolumab

Given 3 mg/kg IV

DRUG

Enzalutamide

given orally per standard of care

Trial Locations (1)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY